AFP via Getty Images Key Takeaways There is increased talk of a potential recession in the cards over the next 12 months Periods of negative economic growth can create a challenging environment for so...
Tag: JNJ
Here Are 6 Stocks That Pay a Lot in Dividends and Have Solid Yields. And Microsoft and Apple.
PepsiCo total quarterly dividend payout and yield make for an intriguing combination. Here, a Pepsi display at a shop in Grovetown, Ga., earlier this year. Billy Blume/Dreamstime.com Text size Sometim...
Focus On Fundamentals In Stormy Markets: Johnson & Johnson (JNJ)
Building of the company Johnson and Johnson in the Juan Carlos I Business Park in Madrid, it is an … [+] American multinational of medical, pharmaceutical and perfumery products, Spain. (Photo b...
JNJ Q1 results: there’s positive narratives in all three of our segments
Shares of Johnson & Johnson (NYSE: JNJ) are down 1.0% in premarket trading on Tuesday after the U.S. company reported weaker-than-expected Q1 revenue and lowered its guidance for the future. J&...
Covid and JNJ earnings Q1 2022
Syringes and a box of Johnson & Johnson vaccine. Paul Hennessy | SOPA Images | LightRocket | Getty Images Johnson & Johnson on Tuesday lowered its full-year sales and earnings outlook, and sto...
Apple and JNJ are two defensive names. Which is better currently?
Apple Inc (NASDAQ:AAPL) has been regarded as the most defensive stock in times of high volatility. Whereas the stock looked strong in the wake of global supply chain challenges, cracks are emerging fr...
Pfizer’s New CFO David Denton Negotiated One of the Biggest Healthcare Deals in History
Pfizer on Monday named a new chief financial officer with a resume that hints at the company’s plans to spend big with its Covid-19 vaccine windfall. David Denton is taking up the CFO role at Pfizer (...
Value Investing Is Back. But How Do You Choose the Right ETF?
Value investing is coming back. Over the past decade, growth stocks have outpaced value shares, which usually have lots of tangible assets relative to their market value. In those 10 years, the S&...
Pfizer, Moderna and J&J Face Shareholder Pressure to Broaden Covid-19 Vaccine Access
Socially conscious investors and global-health activists are turning to shareholders to press Covid-19 vaccine manufacturers Pfizer Inc., Moderna Inc. and Johnson & Johnson to make more of their s...
All 30 Dow stocks rise, led by J&J and UnitedHealth; 3M set to snap longest losing streak in 10 years
The shares of all 30 components of the Dow Jones Industrial Average DJIA, +2.51% gained ground in afternoon trading Friday, as the blue chip barometer surged toward its biggest gain in 21 months. Of t...
Inflation Is Red Hot. How to Protect Your Portfolio and Grow Income.
Income investors—especially those who depend on fixed coupons from bonds—face a hit to their purchasing power as inflation stands above 7%. One strategy to hedge against such big price increases, howe...
How Low Can Bitcoin Go? The Views Vary.
Illustration by Elias Stein Text size Tighter monetary policies are weighing on speculative assets like crypto, Bitcoin crashed from $43,000 to $33,000 in four days and lost 23% of its value. On Jan. ...
Covid and JNJ earnings Q4 2021
The Janssen Johnson & Johnson COVID-19 vaccine. Allen J. Schaben | Los Angeles Times | Getty Images Johnson & Johnson on Tuesday projected that its Covid vaccine would generate $3 billion to $...
Johnson & Johnson’s got a new CEO and a plan to split the company in two. Here’s what else to expect out of J&J’s earnings
Johnson & Johnson JNJ, -0.31% has long been viewed as a bellwether stock for other health care companies, given its early slot in the earnings calendar and a business model that spans everything f...
5 Companies That Began 2022 With Upbeat News on Dividends
Royalty Pharma, Life Storage, and Viatris, among other companies, rang in 2022 by announcing dividend increases this week. Royalty Pharma (ticker: RPRX) declared a quarterly dividend of 19 cents a sha...
Market Volatility Is Creating Opportunities for Stocks. What to Buy Now
The 2022 market was always going to be a tug of war between earnings and interest rates. Corporate profit growth fueled by the reopening has come up against contracting valuations and expectations of ...